Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood
Open Access
- 5 June 2013
- journal article
- research article
- Published by Wiley in ISRN Endocrinology
- Vol. 2013, 1-8
Abstract
Background. Serum lipids including total cholesterol (TC), triglycerides (TG), and low density lipoprotein cholesterol (LDL-C) are increased in pregnancy. Serum proprotein convertase subtilisin kexin 9 (PCSK9) is a significant player in lipoprotein metabolism. Circulating PCSK9 downregulates the LDL receptor on the surface of the liver, inhibiting clearance of LDL-C. Therefore, our study assessed serum PCSK9 concentrations at parturition (Maternal) compared to a nonpregnant (Control) cohort, as well as between mother and newborn (Maternal and Newborn). Methods. Blood was collected from women at parturition and from umbilical cords. Serum lipids and PCSK9 were measured and data were analysed for significance by Mann-Whitney test at and presented as median levels. Spearman's correlations were made at a 95% confidence interval. Results. Serum PCSK9 was significantly higher in Maternal versus Control cohorts (493.1 versus 289.7 ng/mL; , resp.), while the Newborn cohort was significantly lower than Maternal (278.2 versus 493.1 ng/mL; , resp.). PCSK9 was significantly correlated with TC and HDL-C in Maternal and with TC, LDL-C, and HDL-C in Newborn cohorts. Conclusions. Our study provides the first quantitative report on PCSK9 in pregnancy (at parturition) and in umbilical cord blood. Further research will determine how these changes may affect lipoprotein levels during this physiological state.
Keywords
Funding Information
- Heart and Stroke Foundation of Canada
This publication has 31 references indexed in Scilit:
- Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in HumansArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humansJournal of Lipid Research, 2010
- A new method for measurement of total plasma PCSK9: clinical applicationsJournal of Lipid Research, 2010
- Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and AdolescentsClinical Chemistry, 2009
- Genetic and Metabolic Determinants of Plasma PCSK9 LevelsThe Journal of Clinical Endocrinology & Metabolism, 2009
- Plasma PCSK9 levels are significantly modified by statins and fibrates in humansLipids in Health and Disease, 2008
- Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic miceJournal of Clinical Investigation, 2006
- Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProceedings of the National Academy of Sciences, 2004
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences, 2003